Hengrui Pharmaceutical announced that its subsidiary Suzhou Shengdia Biomedical Co., Ltd. received a notice from the State Drug Administration that the third indication of the company's injectable Ruikang trastuzumab was approved for listing for HER2-positive adult patients with HER2-positive colorectal cancer who failed to be treated with oxaliplatin, fluorouracil, and irinotecan, making it the first anti-HER2 product approved for colorectal cancer in China. The drug has been approved for two indications. Up to now, the total R&D investment for related projects is about 2.144 billion yuan. Production and sale of drugs after approval may be affected by uncertainties.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.